

# COVID-19 Impact on Global Dolutegravir/Rilpivirine Combination Drug Market Insights, Forecast to 2026

<https://marketpublishers.com/r/C59FAB828F28EN.html>

Date: July 2020

Pages: 111

Price: US\$ 3,900.00 (Single User License)

ID: C59FAB828F28EN

## Abstracts

Dolutegravir/Rilpivirine Combination Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Dolutegravir/Rilpivirine Combination Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Dolutegravir/Rilpivirine Combination Drug market is segmented into

Self-production API

Outsourcing of API

Segment by Application, the Dolutegravir/Rilpivirine Combination Drug market is segmented into

Hospital

Clinic

Drug Center

Other

### Regional and Country-level Analysis

The Dolutegravir/Rilpivirine Combination Drug market is analysed and market size information is provided by regions (countries).

The key regions covered in the Dolutegravir/Rilpivirine Combination Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

### Competitive Landscape and Dolutegravir/Rilpivirine Combination Drug Market Share Analysis

Dolutegravir/Rilpivirine Combination Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Dolutegravir/Rilpivirine Combination Drug business, the date to enter into the Dolutegravir/Rilpivirine Combination Drug market, Dolutegravir/Rilpivirine Combination Drug product introduction, recent developments, etc.

The major vendors covered:

ViiV Healthcare

JNJ

## Contents

### 1 STUDY COVERAGE

1.1 Dolutegravir/Rilpivirine Combination Drug Product Introduction

1.2 Market Segments

1.3 Key Dolutegravir/Rilpivirine Combination Drug Manufacturers Covered: Ranking by Revenue

1.4 Market by Type

1.4.1 Global Dolutegravir/Rilpivirine Combination Drug Market Size Growth Rate by Type

1.4.2 Self-production API

1.4.3 Outsourcing of API

1.5 Market by Application

1.5.1 Global Dolutegravir/Rilpivirine Combination Drug Market Size Growth Rate by Application

1.5.2 Hospital

1.5.3 Clinic

1.5.4 Drug Center

1.5.5 Other

1.6 Coronavirus Disease 2019 (Covid-19): Dolutegravir/Rilpivirine Combination Drug Industry Impact

1.6.1 How the Covid-19 is Affecting the Dolutegravir/Rilpivirine Combination Drug Industry

1.6.1.1 Dolutegravir/Rilpivirine Combination Drug Business Impact Assessment - Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Dolutegravir/Rilpivirine Combination Drug Potential Opportunities in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Dolutegravir/Rilpivirine Combination Drug Players to Combat Covid-19 Impact

1.7 Study Objectives

1.8 Years Considered

### 2 EXECUTIVE SUMMARY

## 2.1 Global Dolutegravir/Rilpivirine Combination Drug Market Size Estimates and Forecasts

2.1.1 Global Dolutegravir/Rilpivirine Combination Drug Revenue 2015-2026

2.1.2 Global Dolutegravir/Rilpivirine Combination Drug Sales 2015-2026

## 2.2 Dolutegravir/Rilpivirine Combination Drug Market Size by Region: 2020 Versus 2026

2.2.1 Global Dolutegravir/Rilpivirine Combination Drug Retrospective Market Scenario in Sales by Region: 2015-2020

2.2.2 Global Dolutegravir/Rilpivirine Combination Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

## **3 GLOBAL DOLUTEGRAVIR/RILPIVIRINE COMBINATION DRUG COMPETITOR LANDSCAPE BY PLAYERS**

### 3.1 Dolutegravir/Rilpivirine Combination Drug Sales by Manufacturers

3.1.1 Dolutegravir/Rilpivirine Combination Drug Sales by Manufacturers (2015-2020)

3.1.2 Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Manufacturers (2015-2020)

### 3.2 Dolutegravir/Rilpivirine Combination Drug Revenue by Manufacturers

3.2.1 Dolutegravir/Rilpivirine Combination Drug Revenue by Manufacturers (2015-2020)

3.2.2 Dolutegravir/Rilpivirine Combination Drug Revenue Share by Manufacturers (2015-2020)

3.2.3 Global Dolutegravir/Rilpivirine Combination Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)

3.2.4 Global Top 10 and Top 5 Companies by Dolutegravir/Rilpivirine Combination Drug Revenue in 2019

3.2.5 Global Dolutegravir/Rilpivirine Combination Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

### 3.3 Dolutegravir/Rilpivirine Combination Drug Price by Manufacturers

### 3.4 Dolutegravir/Rilpivirine Combination Drug Manufacturing Base Distribution, Product Types

3.4.1 Dolutegravir/Rilpivirine Combination Drug Manufacturers Manufacturing Base Distribution, Headquarters

3.4.2 Manufacturers Dolutegravir/Rilpivirine Combination Drug Product Type

3.4.3 Date of International Manufacturers Enter into Dolutegravir/Rilpivirine Combination Drug Market

### 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

## **4 BREAKDOWN DATA BY TYPE (2015-2026)**

### **4.1 Global Dolutegravir/Rilpivirine Combination Drug Market Size by Type (2015-2020)**

#### **4.1.1 Global Dolutegravir/Rilpivirine Combination Drug Sales by Type (2015-2020)**

#### **4.1.2 Global Dolutegravir/Rilpivirine Combination Drug Revenue by Type (2015-2020)**

#### **4.1.3 Dolutegravir/Rilpivirine Combination Drug Average Selling Price (ASP) by Type (2015-2026)**

### **4.2 Global Dolutegravir/Rilpivirine Combination Drug Market Size Forecast by Type (2021-2026)**

#### **4.2.1 Global Dolutegravir/Rilpivirine Combination Drug Sales Forecast by Type (2021-2026)**

#### **4.2.2 Global Dolutegravir/Rilpivirine Combination Drug Revenue Forecast by Type (2021-2026)**

#### **4.2.3 Dolutegravir/Rilpivirine Combination Drug Average Selling Price (ASP) Forecast by Type (2021-2026)**

### **4.3 Global Dolutegravir/Rilpivirine Combination Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End**

## **5 BREAKDOWN DATA BY APPLICATION (2015-2026)**

### **5.1 Global Dolutegravir/Rilpivirine Combination Drug Market Size by Application (2015-2020)**

#### **5.1.1 Global Dolutegravir/Rilpivirine Combination Drug Sales by Application (2015-2020)**

#### **5.1.2 Global Dolutegravir/Rilpivirine Combination Drug Revenue by Application (2015-2020)**

#### **5.1.3 Dolutegravir/Rilpivirine Combination Drug Price by Application (2015-2020)**

### **5.2 Dolutegravir/Rilpivirine Combination Drug Market Size Forecast by Application (2021-2026)**

#### **5.2.1 Global Dolutegravir/Rilpivirine Combination Drug Sales Forecast by Application (2021-2026)**

#### **5.2.2 Global Dolutegravir/Rilpivirine Combination Drug Revenue Forecast by Application (2021-2026)**

#### **5.2.3 Global Dolutegravir/Rilpivirine Combination Drug Price Forecast by Application (2021-2026)**

## **6 NORTH AMERICA**

### **6.1 North America Dolutegravir/Rilpivirine Combination Drug by Country**

6.1.1 North America Dolutegravir/Rilpivirine Combination Drug Sales by Country

6.1.2 North America Dolutegravir/Rilpivirine Combination Drug Revenue by Country

6.1.3 U.S.

6.1.4 Canada

6.2 North America Dolutegravir/Rilpivirine Combination Drug Market Facts & Figures by Type

6.3 North America Dolutegravir/Rilpivirine Combination Drug Market Facts & Figures by Application

## **7 EUROPE**

7.1 Europe Dolutegravir/Rilpivirine Combination Drug by Country

7.1.1 Europe Dolutegravir/Rilpivirine Combination Drug Sales by Country

7.1.2 Europe Dolutegravir/Rilpivirine Combination Drug Revenue by Country

7.1.3 Germany

7.1.4 France

7.1.5 U.K.

7.1.6 Italy

7.1.7 Russia

7.2 Europe Dolutegravir/Rilpivirine Combination Drug Market Facts & Figures by Type

7.3 Europe Dolutegravir/Rilpivirine Combination Drug Market Facts & Figures by Application

## **8 ASIA PACIFIC**

8.1 Asia Pacific Dolutegravir/Rilpivirine Combination Drug by Region

8.1.1 Asia Pacific Dolutegravir/Rilpivirine Combination Drug Sales by Region

8.1.2 Asia Pacific Dolutegravir/Rilpivirine Combination Drug Revenue by Region

8.1.3 China

8.1.4 Japan

8.1.5 South Korea

8.1.6 India

8.1.7 Australia

8.1.8 Taiwan

8.1.9 Indonesia

8.1.10 Thailand

8.1.11 Malaysia

8.1.12 Philippines

8.1.13 Vietnam

8.2 Asia Pacific Dolutegravir/Rilpivirine Combination Drug Market Facts & Figures by Type

8.3 Asia Pacific Dolutegravir/Rilpivirine Combination Drug Market Facts & Figures by Application

## **9 LATIN AMERICA**

9.1 Latin America Dolutegravir/Rilpivirine Combination Drug by Country

9.1.1 Latin America Dolutegravir/Rilpivirine Combination Drug Sales by Country

9.1.2 Latin America Dolutegravir/Rilpivirine Combination Drug Revenue by Country

9.1.3 Mexico

9.1.4 Brazil

9.1.5 Argentina

9.2 Central & South America Dolutegravir/Rilpivirine Combination Drug Market Facts & Figures by Type

9.3 Central & South America Dolutegravir/Rilpivirine Combination Drug Market Facts & Figures by Application

## **10 MIDDLE EAST AND AFRICA**

10.1 Middle East and Africa Dolutegravir/Rilpivirine Combination Drug by Country

10.1.1 Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Sales by Country

10.1.2 Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Revenue by Country

10.1.3 Turkey

10.1.4 Saudi Arabia

10.1.5 U.A.E

10.2 Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Market Facts & Figures by Type

10.3 Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Market Facts & Figures by Application

## **11 COMPANY PROFILES**

11.1 ViiV Healthcare

11.1.1 ViiV Healthcare Corporation Information

11.1.2 ViiV Healthcare Description, Business Overview and Total Revenue

11.1.3 ViiV Healthcare Sales, Revenue and Gross Margin (2015-2020)



11.1.4 ViiV Healthcare Dolutegravir/Rilpivirine Combination Drug Products Offered

11.1.5 ViiV Healthcare Recent Development

## 11.2 JNJ

11.2.1 JNJ Corporation Information

11.2.2 JNJ Description, Business Overview and Total Revenue

11.2.3 JNJ Sales, Revenue and Gross Margin (2015-2020)

11.2.4 JNJ Dolutegravir/Rilpivirine Combination Drug Products Offered

11.2.5 JNJ Recent Development

## 11.1 ViiV Healthcare

11.1.1 ViiV Healthcare Corporation Information

11.1.2 ViiV Healthcare Description, Business Overview and Total Revenue

11.1.3 ViiV Healthcare Sales, Revenue and Gross Margin (2015-2020)

11.1.4 ViiV Healthcare Dolutegravir/Rilpivirine Combination Drug Products Offered

11.1.5 ViiV Healthcare Recent Development

## 12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)

12.1 Dolutegravir/Rilpivirine Combination Drug Market Estimates and Projections by Region

12.1.1 Global Dolutegravir/Rilpivirine Combination Drug Sales Forecast by Regions 2021-2026

12.1.2 Global Dolutegravir/Rilpivirine Combination Drug Revenue Forecast by Regions 2021-2026

12.2 North America Dolutegravir/Rilpivirine Combination Drug Market Size Forecast (2021-2026)

12.2.1 North America: Dolutegravir/Rilpivirine Combination Drug Sales Forecast (2021-2026)

12.2.2 North America: Dolutegravir/Rilpivirine Combination Drug Revenue Forecast (2021-2026)

12.2.3 North America: Dolutegravir/Rilpivirine Combination Drug Market Size Forecast by Country (2021-2026)

12.3 Europe Dolutegravir/Rilpivirine Combination Drug Market Size Forecast (2021-2026)

12.3.1 Europe: Dolutegravir/Rilpivirine Combination Drug Sales Forecast (2021-2026)

12.3.2 Europe: Dolutegravir/Rilpivirine Combination Drug Revenue Forecast (2021-2026)

12.3.3 Europe: Dolutegravir/Rilpivirine Combination Drug Market Size Forecast by Country (2021-2026)

12.4 Asia Pacific Dolutegravir/Rilpivirine Combination Drug Market Size Forecast



(2021-2026)

12.4.1 Asia Pacific: Dolutegravir/Rilpivirine Combination Drug Sales Forecast

(2021-2026)

12.4.2 Asia Pacific: Dolutegravir/Rilpivirine Combination Drug Revenue Forecast

(2021-2026)

12.4.3 Asia Pacific: Dolutegravir/Rilpivirine Combination Drug Market Size Forecast by Region (2021-2026)

12.5 Latin America Dolutegravir/Rilpivirine Combination Drug Market Size Forecast (2021-2026)

12.5.1 Latin America: Dolutegravir/Rilpivirine Combination Drug Sales Forecast (2021-2026)

12.5.2 Latin America: Dolutegravir/Rilpivirine Combination Drug Revenue Forecast (2021-2026)

12.5.3 Latin America: Dolutegravir/Rilpivirine Combination Drug Market Size Forecast by Country (2021-2026)

12.6 Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Market Size Forecast (2021-2026)

12.6.1 Middle East and Africa: Dolutegravir/Rilpivirine Combination Drug Sales Forecast (2021-2026)

12.6.2 Middle East and Africa: Dolutegravir/Rilpivirine Combination Drug Revenue Forecast (2021-2026)

12.6.3 Middle East and Africa: Dolutegravir/Rilpivirine Combination Drug Market Size Forecast by Country (2021-2026)

## **13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS**

13.1 Market Opportunities and Drivers

13.2 Market Challenges

13.3 Market Risks/Restraints

13.4 Porter's Five Forces Analysis

13.5 Primary Interviews with Key Dolutegravir/Rilpivirine Combination Drug Players (Opinion Leaders)

## **14 VALUE CHAIN AND SALES CHANNELS ANALYSIS**

14.1 Value Chain Analysis

14.2 Dolutegravir/Rilpivirine Combination Drug Customers

14.3 Sales Channels Analysis

14.3.1 Sales Channels

14.3.2 Distributors

## **15 RESEARCH FINDINGS AND CONCLUSION**

## **16 APPENDIX**

16.1 Research Methodology

16.1.1 Methodology/Research Approach

16.1.2 Data Source

16.2 Author Details

## List Of Tables

### LIST OF TABLES

Table 1. Dolutegravir/Rilpivirine Combination Drug Market Segments

Table 2. Ranking of Global Top Dolutegravir/Rilpivirine Combination Drug Manufacturers by Revenue (US\$ Million) in 2019

Table 3. Global Dolutegravir/Rilpivirine Combination Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US\$ Million)

Table 4. Major Manufacturers of Self-production API

Table 5. Major Manufacturers of Outsourcing of API

Table 6. COVID-19 Impact Global Market: (Four Dolutegravir/Rilpivirine Combination Drug Market Size Forecast Scenarios)

Table 7. Opportunities and Trends for Dolutegravir/Rilpivirine Combination Drug Players in the COVID-19 Landscape

Table 8. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 9. Key Regions/Countries Measures against Covid-19 Impact

Table 10. Proposal for Dolutegravir/Rilpivirine Combination Drug Players to Combat Covid-19 Impact

Table 11. Global Dolutegravir/Rilpivirine Combination Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)

Table 12. Global Dolutegravir/Rilpivirine Combination Drug Market Size by Region (K Pcs) & (US\$ Million): 2020 VS 2026

Table 13. Global Dolutegravir/Rilpivirine Combination Drug Sales by Regions 2015-2020 (K Pcs)

Table 14. Global Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Regions (2015-2020)

Table 15. Global Dolutegravir/Rilpivirine Combination Drug Revenue by Regions 2015-2020 (US\$ Million)

Table 16. Global Dolutegravir/Rilpivirine Combination Drug Sales by Manufacturers (2015-2020) (K Pcs)

Table 17. Global Dolutegravir/Rilpivirine Combination Drug Sales Share by Manufacturers (2015-2020)

Table 18. Global Dolutegravir/Rilpivirine Combination Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)

Table 19. Global Dolutegravir/Rilpivirine Combination Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dolutegravir/Rilpivirine Combination Drug as of 2019)

Table 20. Dolutegravir/Rilpivirine Combination Drug Revenue by Manufacturers

(2015-2020) (US\$ Million)

Table 21. Dolutegravir/Rilpivirine Combination Drug Revenue Share by Manufacturers (2015-2020)

Table 22. Key Manufacturers Dolutegravir/Rilpivirine Combination Drug Price (2015-2020) (USD/Pcs)

Table 23. Dolutegravir/Rilpivirine Combination Drug Manufacturers Manufacturing Base Distribution and Headquarters

Table 24. Manufacturers Dolutegravir/Rilpivirine Combination Drug Product Type

Table 25. Date of International Manufacturers Enter into Dolutegravir/Rilpivirine Combination Drug Market

Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 27. Global Dolutegravir/Rilpivirine Combination Drug Sales by Type (2015-2020) (K Pcs)

Table 28. Global Dolutegravir/Rilpivirine Combination Drug Sales Share by Type (2015-2020)

Table 29. Global Dolutegravir/Rilpivirine Combination Drug Revenue by Type (2015-2020) (US\$ Million)

Table 30. Global Dolutegravir/Rilpivirine Combination Drug Revenue Share by Type (2015-2020)

Table 31. Dolutegravir/Rilpivirine Combination Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)

Table 32. Global Dolutegravir/Rilpivirine Combination Drug Sales by Application (2015-2020) (K Pcs)

Table 33. Global Dolutegravir/Rilpivirine Combination Drug Sales Share by Application (2015-2020)

Table 34. North America Dolutegravir/Rilpivirine Combination Drug Sales by Country (2015-2020) (K Pcs)

Table 35. North America Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Country (2015-2020)

Table 36. North America Dolutegravir/Rilpivirine Combination Drug Revenue by Country (2015-2020) (US\$ Million)

Table 37. North America Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Country (2015-2020)

Table 38. North America Dolutegravir/Rilpivirine Combination Drug Sales by Type (2015-2020) (K Pcs)

Table 39. North America Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Type (2015-2020)

Table 40. North America Dolutegravir/Rilpivirine Combination Drug Sales by Application (2015-2020) (K Pcs)

Table 41. North America Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Application (2015-2020)

Table 42. Europe Dolutegravir/Rilpivirine Combination Drug Sales by Country (2015-2020) (K Pcs)

Table 43. Europe Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Country (2015-2020)

Table 44. Europe Dolutegravir/Rilpivirine Combination Drug Revenue by Country (2015-2020) (US\$ Million)

Table 45. Europe Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Country (2015-2020)

Table 46. Europe Dolutegravir/Rilpivirine Combination Drug Sales by Type (2015-2020) (K Pcs)

Table 47. Europe Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Type (2015-2020)

Table 48. Europe Dolutegravir/Rilpivirine Combination Drug Sales by Application (2015-2020) (K Pcs)

Table 49. Europe Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Application (2015-2020)

Table 50. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Sales by Region (2015-2020) (K Pcs)

Table 51. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Region (2015-2020)

Table 52. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Revenue by Region (2015-2020) (US\$ Million)

Table 53. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Region (2015-2020)

Table 54. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Sales by Type (2015-2020) (K Pcs)

Table 55. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Type (2015-2020)

Table 56. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Sales by Application (2015-2020) (K Pcs)

Table 57. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Application (2015-2020)

Table 58. Latin America Dolutegravir/Rilpivirine Combination Drug Sales by Country (2015-2020) (K Pcs)

Table 59. Latin America Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Country (2015-2020)

Table 60. Latin Americaa Dolutegravir/Rilpivirine Combination Drug Revenue by

Country (2015-2020) (US\$ Million)

Table 61. Latin America Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Country (2015-2020)

Table 62. Latin America Dolutegravir/Rilpivirine Combination Drug Sales by Type (2015-2020) (K Pcs)

Table 63. Latin America Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Type (2015-2020)

Table 64. Latin America Dolutegravir/Rilpivirine Combination Drug Sales by Application (2015-2020) (K Pcs)

Table 65. Latin America Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Application (2015-2020)

Table 66. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Sales by Country (2015-2020) (K Pcs)

Table 67. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Country (2015-2020)

Table 68. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Revenue by Country (2015-2020) (US\$ Million)

Table 69. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Country (2015-2020)

Table 70. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Sales by Type (2015-2020) (K Pcs)

Table 71. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Type (2015-2020)

Table 72. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Sales by Application (2015-2020) (K Pcs)

Table 73. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Application (2015-2020)

Table 74. ViiV Healthcare Corporation Information

Table 75. ViiV Healthcare Description and Major Businesses

Table 76. ViiV Healthcare Dolutegravir/Rilpivirine Combination Drug Production (K Pcs), Revenue (US\$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 77. ViiV Healthcare Product

Table 78. ViiV Healthcare Recent Development

Table 79. JNJ Corporation Information

Table 80. JNJ Description and Major Businesses

Table 81. JNJ Dolutegravir/Rilpivirine Combination Drug Production (K Pcs), Revenue (US\$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 82. JNJ Product

Table 83. JNJ Recent Development



Table 84. Global Dolutegravir/Rilpivirine Combination Drug Sales Forecast by Regions (2021-2026) (K Pcs)

Table 85. Global Dolutegravir/Rilpivirine Combination Drug Sales Market Share Forecast by Regions (2021-2026)

Table 86. Global Dolutegravir/Rilpivirine Combination Drug Revenue Forecast by Regions (2021-2026) (US\$ Million)

Table 87. Global Dolutegravir/Rilpivirine Combination Drug Revenue Market Share Forecast by Regions (2021-2026)

Table 88. North America: Dolutegravir/Rilpivirine Combination Drug Sales Forecast by Country (2021-2026) (K Pcs)

Table 89. North America: Dolutegravir/Rilpivirine Combination Drug Revenue Forecast by Country (2021-2026) (US\$ Million)

Table 90. Europe: Dolutegravir/Rilpivirine Combination Drug Sales Forecast by Country (2021-2026) (K Pcs)

Table 91. Europe: Dolutegravir/Rilpivirine Combination Drug Revenue Forecast by Country (2021-2026) (US\$ Million)

Table 92. Asia Pacific: Dolutegravir/Rilpivirine Combination Drug Sales Forecast by Region (2021-2026) (K Pcs)

Table 93. Asia Pacific: Dolutegravir/Rilpivirine Combination Drug Revenue Forecast by Region (2021-2026) (US\$ Million)

Table 94. Latin America: Dolutegravir/Rilpivirine Combination Drug Sales Forecast by Country (2021-2026) (K Pcs)

Table 95. Latin America: Dolutegravir/Rilpivirine Combination Drug Revenue Forecast by Country (2021-2026) (US\$ Million)

Table 96. Middle East and Africa: Dolutegravir/Rilpivirine Combination Drug Sales Forecast by Country (2021-2026) (K Pcs)

Table 97. Middle East and Africa: Dolutegravir/Rilpivirine Combination Drug Revenue Forecast by Country (2021-2026) (US\$ Million)

Table 98. Key Opportunities and Drivers: Impact Analysis (2021-2026)

Table 99. Key Challenges

Table 100. Market Risks

Table 101. Main Points Interviewed from Key Dolutegravir/Rilpivirine Combination Drug Players

Table 102. Dolutegravir/Rilpivirine Combination Drug Customers List

Table 103. Dolutegravir/Rilpivirine Combination Drug Distributors List

Table 104. Research Programs/Design for This Report

Table 105. Key Data Information from Secondary Sources

Table 106. Key Data Information from Primary Sources



## List Of Figures

### LIST OF FIGURES

Figure 1. Dolutegravir/Rilpivirine Combination Drug Product Picture

Figure 2. Global Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Type in 2020 & 2026

Figure 3. Self-production API Product Picture

Figure 4. Outsourcing of API Product Picture

Figure 5. Global Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Application in 2020 & 2026

Figure 6. Hospital

Figure 7. Clinic

Figure 8. Drug Center

Figure 9. Other

Figure 10. Dolutegravir/Rilpivirine Combination Drug Report Years Considered

Figure 11. Global Dolutegravir/Rilpivirine Combination Drug Market Size 2015-2026 (US\$ Million)

Figure 12. Global Dolutegravir/Rilpivirine Combination Drug Sales 2015-2026 (K Pcs)

Figure 13. Global Dolutegravir/Rilpivirine Combination Drug Market Size Market Share by Region: 2020 Versus 2026

Figure 14. Global Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Region (2015-2020)

Figure 15. Global Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Region in 2019

Figure 16. Global Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Region (2015-2020)

Figure 17. Global Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Region in 2019

Figure 18. Global Dolutegravir/Rilpivirine Combination Drug Sales Share by Manufacturer in 2019

Figure 19. The Top 10 and 5 Players Market Share by Dolutegravir/Rilpivirine Combination Drug Revenue in 2019

Figure 20. Dolutegravir/Rilpivirine Combination Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019

Figure 21. Global Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Type (2015-2020)

Figure 22. Global Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Type in 2019

Figure 23. Global Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Type (2015-2020)

Figure 24. Global Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Type in 2019

Figure 25. Global Dolutegravir/Rilpivirine Combination Drug Market Share by Price Range (2015-2020)

Figure 26. Global Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Application (2015-2020)

Figure 27. Global Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Application in 2019

Figure 28. Global Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Application (2015-2020)

Figure 29. Global Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Application in 2019

Figure 30. North America Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate 2015-2020 (K Pcs)

Figure 31. North America Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate 2015-2020 (US\$ Million)

Figure 32. North America Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Country in 2019

Figure 33. North America Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Country in 2019

Figure 34. U.S. Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 35. U.S. Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 36. Canada Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 37. Canada Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 38. North America Dolutegravir/Rilpivirine Combination Drug Market Share by Type in 2019

Figure 39. North America Dolutegravir/Rilpivirine Combination Drug Market Share by Application in 2019

Figure 40. Europe Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate 2015-2020 (K Pcs)

Figure 41. Europe Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate 2015-2020 (US\$ Million)

Figure 42. Europe Dolutegravir/Rilpivirine Combination Drug Sales Market Share by

Country in 2019

Figure 43. Europe Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Country in 2019

Figure 44. Germany Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 45. Germany Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 46. France Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 47. France Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 48. U.K. Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 49. U.K. Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 50. Italy Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 51. Italy Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 52. Russia Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 53. Russia Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 54. Europe Dolutegravir/Rilpivirine Combination Drug Market Share by Type in 2019

Figure 55. Europe Dolutegravir/Rilpivirine Combination Drug Market Share by Application in 2019

Figure 56. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate 2015-2020 (K Pcs)

Figure 57. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate 2015-2020 (US\$ Million)

Figure 58. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Region in 2019

Figure 59. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Region in 2019

Figure 60. China Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 61. China Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 62. Japan Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 63. Japan Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 64. South Korea Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 65. South Korea Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 66. India Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 67. India Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 68. Australia Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 69. Australia Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 70. Taiwan Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 71. Taiwan Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 72. Indonesia Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 73. Indonesia Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 74. Thailand Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 75. Thailand Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 76. Malaysia Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 77. Malaysia Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 78. Philippines Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 79. Philippines Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 80. Vietnam Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 81. Vietnam Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate

(2015-2020) (US\$ Million)

Figure 82. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Market Share by Type in 2019

Figure 83. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Market Share by Application in 2019

Figure 84. Latin America Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate 2015-2020 (K Pcs)

Figure 85. Latin America Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate 2015-2020 (US\$ Million)

Figure 86. Latin America Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Country in 2019

Figure 87. Latin America Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Country in 2019

Figure 88. Mexico Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 89. Mexico Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 90. Brazil Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 91. Brazil Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 92. Argentina Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 93. Argentina Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 94. Latin America Dolutegravir/Rilpivirine Combination Drug Market Share by Type in 2019

Figure 95. Latin America Dolutegravir/Rilpivirine Combination Drug Market Share by Application in 2019

Figure 96. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate 2015-2020 (K Pcs)

Figure 97. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate 2015-2020 (US\$ Million)

Figure 98. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Country in 2019

Figure 99. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Country in 2019

Figure 100. Turkey Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 101. Turkey Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 102. Saudi Arabia Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 103. Saudi Arabia Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 104. U.A.E Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate (2015-2020) (K Pcs)

Figure 105. U.A.E Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 106. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Market Share by Type in 2019

Figure 107. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Market Share by Application in 2019

Figure 108. ViiV Healthcare Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 109. JNJ Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 110. North America Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)

Figure 111. North America Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate Forecast (2021-2026) (US\$ Million)

Figure 112. Europe Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)

Figure 113. Europe Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate Forecast (2021-2026) (US\$ Million)

Figure 114. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)

Figure 115. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate Forecast (2021-2026) (US\$ Million)

Figure 116. Latin America Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)

Figure 117. Latin America Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate Forecast (2021-2026) (US\$ Million)

Figure 118. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)

Figure 119. Middle East and Africa Dolutegravir/Rilpivirine Combination Drug Revenue Growth Rate Forecast (2021-2026) (US\$ Million)

Figure 120. Porter's Five Forces Analysis

Figure 121. Channels of Distribution

Figure 122. Distributors Profiles



Figure 123. Bottom-up and Top-down Approaches for This Report

Figure 124. Data Triangulation

Figure 125. Key Executives Interviewed



## I would like to order

Product name: COVID-19 Impact on Global Dolutegravir/Rilpivirine Combination Drug Market Insights, Forecast to 2026

Product link: <https://marketpublishers.com/r/C59FAB828F28EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C59FAB828F28EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

